Home

Editor's Choice

Alzheimer’s Drug Pulled From Phase III for Lack of EfficacyAlzheimer’s Drug Pulled From Phase III for Lack of Efficacy

Another potential Alzheimer’s disease drug failed after Eli Lilly and Co. pulled the plug Aug. 17 on its phase III study of semagacestat, a gamma secretase inhibitor designed to reduce the aggregation of beta-amyloid into brain plaques... 

Psychiatry News

 
Depression Common Among Doctors  
Depression and anxiety among doctors is common, with suicide rates above the national average, a doc...
 
Alzheimer’s Drug Pulled From Phase III for Lack of Efficacy  
Another potential Alzheimer’s disease drug failed after Eli Lilly and Co. pulled the plug Aug. 17 on...
 
Insulin Resistance, Alzheimer's Link  
People with insulin resistance and type 2 diabetes are at higher risk of developing plaques associat...
 
Perspective – Is Decluttering a Form of Therapy?  
Requests for professional intervention for people who are disorganized, surrounded by clutter, and o...
 
New Data Blur Typical-Atypical Drug Distinctions  
The line between typical and atypical (first- and second-generation) antipsychotic medications is be...
Psychiatry Journal Summaries
MedConnect's Journal Summaries provide article summaries of the latest research from the top general interest journals updated with each new issue release.